The Michael J. Fox Foundation continually strives to communicate our scientific progress with the research community — through posters and presentations at meetings, in peer-reviewed scientific publications and with white paper reports.
-
-
-
-
-
The Michael J. Fox Foundation’s development and distribution of novel alpha-synuclein viral vectors to study Parkinson's disease.
-
LRRK2 inhibitors induce reversible changes in nonhuman primate lungs without measurable pulmonary deficits
-
The Michael J. Fox Foundation’s Efforts to Understand the Relationship between GBA1 and Alpha-Synuclein through the Development and Characterization of Preclinical Models
Articles authored by Rachel Dolhun, MD, a movement disorder specialist on staff at MJFF, offer a practical review of topics related to Parkinson's disease for practicing clinicians.
No results were found.
![Female researcher pipetting in lab.](/sites/default/files/styles/ad_callout_single/public/images/ad/research-news-404---Large-Image-Callout-A-1.jpg?h=ef0d82ac&itok=eyoWusm3)
Breaking Research Updates
Read the latest developments in the field’s understanding and treatment of Parkinson’s disease.